← All Okyo Pharma LTD filings

Okyo Pharma LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
OKYO
Okyo Pharma LTD
20-F: OKYO Pharma Reports FY26 Results, Focuses on Urcosimod
OKYO Pharma Limited filed its Form 20-F for the fiscal year ended March 31, 2026, detailing its ongoing development of urcosimod for neuropathic corneal pain and its financial performance.
NASDAQ
OKYO
Okyo Pharma LTD
20-F/A: OKYO Pharma Amends 20-F to Add Clawback Policy
OKYO Pharma Limited filed an amendment to its annual report to include a new Clawback Policy for executive incentive compensation.
NASDAQ
OKYO
Okyo Pharma LTD
20-F: OKYO Pharma Reports Mixed Financials Amid Strategic Shift to Neuropathic Corneal Pain and Fast Track Designation
OKYO Pharma Limited reported a reduced net loss for the fiscal year ended March 31, 2025, driven by lower R&D and administrative expenses, while strategically accelerating its lead drug candidate urcosimod for neuropathic corneal pain after receiving Fast Track designation.
NASDAQ
OKYO
Okyo Pharma LTD
20-F: OKYO Pharma Reports Fiscal Year 2024 Results, Highlights Progress in Dry Eye Disease and Neuropathic Corneal Pain Programs
OKYO Pharma's fiscal year 2024 results highlight advancements in their OK-101 clinical program for dry eye disease and neuropathic corneal pain, despite ongoing financial challenges.